Bayer AG Reports Strong Q4 Earnings

Bayer AG experienced a significant surge in its stock prices this Wednesday, following the announcement of its fourth-quarter earnings for fiscal 2024. The German pharmaceutical giant not only exceeded analysts' expectations but also provided a hopeful outlook for the future, despite anticipating a challenging 2025.

Financial Highlights

The company disclosed an EBITDA of €1.9 billion and sales amounting to €11.7 billion for the quarter ending December 2024. These figures not only surpassed the forecasts but also underscored Bayer's robust financial health amidst a challenging economic landscape.

Future Outlook

Despite labeling 2025 as potentially the most financially challenging year, Bayer remains optimistic about achieving improved performance starting from 2026. This forward-looking statement, coupled with the strong earnings report, propelled Bayer's shares to a 4.70% increase, trading at €24.63 per share at 11:58 am CET.